Shares mag. recommending this stock this week. Is this going to be our killer this christmas!!!! any comments anyone?????

Hey, nice one Queenie!

Merci parthus

Just had another look Queenie and your p*ssing in the wind mate.

Go and buy something tidy for once in you life.

Regards

xxx

Dilbert it's taken you 2 whole days to come up with that response. Is that really the best you could do?! Perhaps the sheep on the top field weren't playing the game and kept running for cover. Either way, as ever your insightful commentary has kept myself and other posters glued to the edge of their keyboards and we thank you for your infinite wisdom.

No probs mate , just ask I'm always willing to help a dickhead .

Again Dil-ute, such economy of word, such eloquent turn of phrase.

And I've noticed you've followed me onto the BIFF thread as well - anywhere in fact that I seem to post. And the thing I don't understand is that I'm not even wearing wool.

does anyone have access to information on institution holdings compared to issued shares please?

FYI. Substantial shareholdings

Avlar Bioventures Fund II 26,807,760 6.5
Gandhara Capital Master Fund Limited 26,252,626 6.4
UBS AG 22,146,632 5.4
R G Robb 17,000,000 4.1
Alan Goodman 15,843,866 3.9
GlaxoSmithKline plc 13,284,508 3.2

http://www.cenes.com/investor/financial_reports.htm

Thanks johnny

And some more positive news:-

Cambridge, UK, 20th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces new data on its short-acting sedative, CNS 7056. These preclinical data show that CNS 7056 induces deep sedation, has a rapid onset of action and rapid offset of action with predictable effects over a wide range of doses. On the basis of this successful outcome, the compound will be developed for the indications of induction and maintenance of anaesthesia in addition to sedation for day-case procedures. CeNeS also announces that the first full academic paper on CNS 7056 will be published in the July issue of the leading journal Anesthesiology. The paper is one of a small number highlighted in the introductory section of this issue.


Additional indications

Following the successful completion of studies at the University of Adelaide and under a material transfer agreement with an International Pharmaceutical company, CeNeS will develop CNS 7056 for the induction and maintenance of anaesthesia in addition to the existing development for sedation during day-case procedures. These latest pre-clinical studies show that CNS 7056 has the desirable features for an anaesthetic drug of inducing deep sedation rapidly and controllably, with predictable effects over a wide range of doses and a rapid recovery.


Academic publication

CeNeS is pleased to note that the first full academic paper on CNS 7056 will be published in the July issue of the leading international Journal Anesthesiology and has been selected as a featured article for the section this month in Anesthesiology.



Neil Clark, Chief Executive of CeNeS commented: CNS 7056 shows an excellent profile in preclinical studies. Development for the additional indications of the induction and maintenance of anaesthesia means that the market potential is significantly larger. We believe that the peak sales opportunity for this compound is now doubled to 400m. We are looking forward to filing an IND for this compound in the next few months and commencing Phase I clinical trials.

CNS 7056 exemplifies CeNeS strategy of focussing on low-risk programmes that provide early and simple proof of concept in clinical trials. Indeed, an important feature of this development programme is that we will be able to generate proof of concept data on sedation/anaesthesia in Phase I volunteer studies rather than having to wait for Phase II patient studies as is the case for most drug development programmes.

Barclays let me have another tranche at 5.11p this morning --- sub mid price.

So all the 5.11 and 5.12 deals are most likely to be purchases today. I guess they knew there was a 4.2m line coming along....

There has been some positive news recently but sp is still heading south. Why? The chairman at the end of RNS this morning said "our stated aim of partnerning our lead product is going as planned". I suppose the sp will not be changing direction until a licensing deal is struck. Does anyone have any idea when the sp is going to break through 8 or 9p?

When they strike a deal, or rumour of an impending deal hits the streets. Very hit and miss these R&D druggies, but if any of their development drugs become fully commercialsed and M6G certainly has a fighting chance, 8/9p will be but a distant memory. Shit or bust when investing in this sector and it can take years of patience to see a return on investment, but if there is a return, it can be pretty spectacular. Stick 'em in the bottom drawer and forget all about them, unless you need the funds for summat else.

pth

These must be a bargain at these prices?

CYNIC where are you?

These must be a bargain at these prices?

CYNIC where are you?

They are placing over 6 million of shares at a price of 3.5p and next chart support is around 2p.

I'm no guru but I wouldn't touch them at this price.

Dil,i will watch with interest and if they hit 2p,i will BUY!.

Price getting clobbered now capetown , wise to wait.

Have put a buy order 2p limit,doubt it will fall as far,but for once i will wait and see.

more to the point, why would you buy? ...... no obvious reason that i can see